- Anti-HIV drugs, licensed single class agents
- Anti-HIV drugs, licensed, fixed-dose combination class
- Investigational anti-HIV drugs and treatments
- Alovudine
- ALVAC 1433
- AMD070
- Apricitabine (AVX754, SPD754)
- Bevirimat (PA-457)
- BMS-488043
- Calanolide A
- CD4-based therapies
- Cell Genesys gene therapy
- Cimetidine (Dyspamet / Tagamet)
- Colony stimulating factors
- Curcumin
- Dapivirine
- Dextran sulphate
- Dinitrochlorobenzene (DNCB)
- Elvitegravir (GS-9137)
- Elvucitabine (ACH-126)
- Extracorporeal photopheresis
- FP-21399
- GPG-NH2
- GW695634
- GW8248
- HEPT derivatives
- HGP-30
- HGTV43
- Hydroxycarbamide (Hydrea)
- Hyperthermia
- Interferon gamma-1b (Immukin)
- Interleukin-12
- Interleukin-16
- Intravenous immunoglobulin
- Iscador
- Isoprinosine
- JE-2147
- Lentinan
- Malariotherapy
- MIV 150
- MVA-BN-Nef vaccine
- Mycophenolate mofetil (CellCept)
- Ozone
- P-1946
- p24.VLP
- Passive immunotherapy
- Phosphazid
- PN355
- PRO 2000
- PRO 140
- pTHr.HIVA
- Racivir
- Remune
- S-1360
- SJ-3366
- SP1093V
- SPV-30
- Stampidine
- Tat toxoid vaccine
- Thymic peptides
- TMC278
- TNFR:Fc
- TNX-355
- Todoxin
- TSAO derivatives
- Tucaresol
- Vesnarinone
- Vicriviroc
- VIR201
- Virodene P058
- WF10
- Other drugs
- Herbal and naturopathic treatments
- Discontinued anti-HIV drugs
Investigational anti-HIV drugs and treatments
- Alovudine
- ALVAC 1433
- AMD070
- Apricitabine (AVX754, SPD754)
- Bevirimat (PA-457)
- BMS-488043
- Calanolide A
- CD4-based therapies
- Cell Genesys gene therapy
- Cimetidine (Dyspamet / Tagamet)
- Colony stimulating factors
- Curcumin
- Dapivirine
- Dextran sulphate
- Dinitrochlorobenzene (DNCB)
- Elvitegravir (GS-9137)
- Elvucitabine (ACH-126)
- Extracorporeal photopheresis
- FP-21399
- GPG-NH2
- GW695634
- GW8248
- HEPT derivatives
- HGP-30
- HGTV43
- Hydroxycarbamide (Hydrea)
- Hyperthermia
- Interferon gamma-1b (Immukin)
- Interleukin-12
- Interleukin-16
- Intravenous immunoglobulin
- Iscador
- Isoprinosine
- JE-2147
- Lentinan
- Malariotherapy
- MIV 150
- MVA-BN-Nef vaccine
- Mycophenolate mofetil (CellCept)
- Ozone
- P-1946
- p24.VLP
- Passive immunotherapy
- Phosphazid
- PN355
- PRO 2000
- PRO 140
- pTHr.HIVA
- Racivir
- Remune
- S-1360
- SJ-3366
- SP1093V
- SPV-30
- Stampidine
- Tat toxoid vaccine
- Thymic peptides
- TMC278
- TNFR:Fc
- TNX-355
- Todoxin
- TSAO derivatives
- Tucaresol
- Vesnarinone
- Vicriviroc
- VIR201
- Virodene P058
- WF10
latest aidsmap news
- HIV prevalence may decline because the most vulnerable are infected and die first
- Lack of perceived need for HIV treatment associated with poor adherence
- TB doesn't always increase HIV viral load
- New 75mg darunavir tablet approved by FDA for use by HIV-positive children
- Thyroid checks recommended for people with HIV
- Knighthood for head of UK HIV charity
- Gay men often not accessing PEP despite risk of HIV exposure
- Inflammatory cytokines may contribute to endothelial dysfunction in people with untreated HIV
- Internalised homophobia leads to sexual risk taking by HIV-positive gay men
- Most gay men willing to consider PrEP for possible HIV exposure